

Obsessive-compulsive disorder, major depressive disorder, and addiction: the vicious relationship

Rifaat S. El-Mallakh,¹ Jamal Shams,² Moein Doroodgar,³ Masoud Doroodgar³

¹Department of Psychiatry, University of Louisville, School of Medicine, Louisville, United States of America; ²Behavioral Sciences Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran; ³School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

This article is distributed under the terms of the Creative Commons Attribution Noncommercial License (CC BY-NC 4.0) which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.

Abstract

Obsessive-Compulsive Disorder (OCD) and Major Depressive Disorder (MDD) are prevalent psychiatric conditions, each affecting a substantial portion of the global population. When these conditions coexist with a Substance Use Disorder (SUD), the complexity of the clinical presentation is heightened. Herein, we describe two cases of individuals who have comorbid OCD and/or MDD and substance use disorder that highlight the importance of addressing the coexisting psychiatric illness when treating the SUD. These cases highlight the importance of tailored, multidisciplinary care, offering a potential therapeutic strategy based on medications for comprehensive recovery in individuals facing complex comorbid disorders. An integrated treatment approach, encompassing both psychiatric and substance treatment perspectives, is imperative.

Key Words: comorbidity; major depressive disorder; obsessive compulsive disorder; substance use disorders.

Eur J Transl Myol 34 (4) 13108, 2024 doi: 10.4081/ejtm.2024.13108

Substance Use Disorders (SUDs) frequently co-occur with other psychiatric illnesses.¹ Substance use disorders manifest by a frequently relapsing inability to control consumption of legal or illegal drugs, alcohol, or medications with consequent emotional, behavioral, or functional dysfunction.^{2,3} In the United States in 2007, SUDs resulted in some \$193 billion in direct and indirect costs,⁴ and tragically, the rate of accidental opiate overdose deaths increased by 1,040% from 2013 to 2019 and continues to increase now, although at a more modest rate.⁵ Over half of individuals with a SUD have a co-occurring psychiatric illness.⁶

Obsessive-Compulsive Disorder (OCD) is a mental illness that manifests with repeated unwanted thoughts or sensations (obsessions) and urge to do something repeatedly again (compulsions); some people have both obsessions and compulsions.⁷ In earlier editions of the Diagnostic and Statistical Manual (DSM), OCD was classified as an anxiety disorder. This was changed with the 5th edition of the DSM when OCD was placed into a new category of Obsessive-Compulsive and Related Disorders.⁸ Nonetheless, OCD and anxiety disorders are among the most common psychiatric co-morbidities in people with SUDs.⁹ Individ-

uals with Obsessive-Compulsive Disorder (OCD) have a 3.7-fold elevated risk of having a concomitant SUD¹⁰ and those with a SUD comprise about 25% of those seeking treatment for OCD.¹¹

OCD is also highly co-morbid with Major Depressive Disorder (MDD) with a 32% incidence of comorbidity and a lifetime prevalence of 67.5%.¹¹ Comorbidity of SUD with both MDD and SUD is about 25% and higher in males (36%) than females (19%).¹³ The co-occurrence of SUD alongside OCD and depression represents a pivotal challenge in psychiatric care, demanding heightened attention due to its profound impact on the course, prognosis, and treatment outcomes of these complex mental health conditions.¹⁴ The intricate interplay between OCD, MDD, and addiction is a subject of increasing significance within the fields of psychiatry and addiction medicine. The comorbidity of these conditions poses a unique clinical challenge, as each condition can fuel the course of the others, leading to treatment resistance and prolonged suffering for affected individuals.^{2,15,16} The necessity of addressing this complexity is underscored by the growing recognition of the role of SUDs, such as opioid use, in exacerbating psychiatric symptoms and, on the other hand, the role of

psychiatric disorders in worsening addiction and complicating treatment efforts.

When SUDs co-occur with a psychiatric illness, integrating the treatment approaches is associated with the best outcomes.¹⁷⁻¹⁹ For example, in the treatment of comorbid MDD and alcohol use disorder, the use of a Serotonin-Reuptake Inhibiting (SRI) medication was associated with improved alcohol-related outcomes.²⁰ Similarly, tricyclic antidepressants, but not SRIs, were associated with improved mood outcomes in patients with co-occurring MDD and opiate use disorder.²¹ Despite the documentation of greater comorbidity of OCD and SUD,¹⁰ and the demonstration of the utility of SRIs in the management of OCD,²² there is a dearth of data on the use of SRIs in dual diagnosis OCD plus SUD. In this report we present two patients with opiate use disorder and comorbid psychiatric conditions. One patient with comorbid OCD was able to discontinue methadone co-treatment after initiation of sertraline and quetiapine. A patient with comorbid MDD was able to reduce his methadone dose to 20 mg daily after initiating treatment with bupropion and aripiprazole. These cases demonstrate the importance of addressing comorbid psychiatric disorders in the treatment of opiate use disorder.

Case Reports

Case A

A 37-year-old man with a history of high-dose methadone abuse for several years was referred to the Addiction Treatment Center for management of methadone dosage. A careful psychiatric evaluation uncovered OCD in addition to opiate use disorder. There was no previous treatment for OCD. He was treated with sertraline 50 mg daily and quetiapine 25 mg at bedtime, and after 3 weeks of treatment, he was started on a methadone taper, the dose of methadone from 80mg daily to off over 22 days. During this period, he was also prescribed naproxen 250 mg twice daily to control somatic pain. Follow-up at four weeks found the patient still taking sertraline and quetiapine and free of opiate cravings.

Case B

A 35-year-old man with a history of chronic dependence on methadone, with a daily dose of 120 mg for the past two years, sought treatment for a complex clinical presentation involving comorbid OCD and Depression. Treatment was initiated with bupropion at 150 mg every morning, along with aripiprazole 5 mg every evening. Concurrently, a gradual taper of methadone dose was initiated. Over a span of six weeks, the collaborative efforts of the clinical team and the patient culminated in the successful discontinuation of methadone. At follow-up in four weeks, the patient was still taking bupropion and aripiprazole, and still off all opioid substances.

Discussion

There are increasing lines of evidence that suggest that the relationship between the cooccurring of OCD and SUD is

especially complex.²³ Comorbidity of the two conditions may be particularly problematic with patients suffering reduced levels of functioning¹¹ and increased risk of suicide.²⁴ Additionally, the effect of substances is variable. Among individuals with OCD, use of stimulants may exacerbate OCD symptoms,²⁵ while opiates may alleviate those symptoms.²⁶ In the majority of patients (70%), the onset of OCD precedes the onset of SUD,¹¹ supporting the hypothesis that some substances may alleviate OCD symptoms.¹⁰ Alternatively, the predilection to obsessive thoughts and compulsive behaviors can fuel substance use by increasing obsession with using the drug or engaging compulsively in drug-using rituals. Whatever the nature of the relationship, coexistence of OCD and SUD is strong and can lead to undesirable consequences;²³ a situation that is exacerbated if the patient also suffers from MDD.^{27,28}

OCD, characterized by intrusive and distressing obsessions and compulsions,²⁹ is often intertwined with MDD, marked by pervasive and debilitating sadness.³⁰ This intricate interplay between OCD and depression adds layers of complexity to the clinical presentation, making it a multifaceted challenge to address. The presence of addiction in this context further compounds the complexity. Both OCD and depression can hinder the effectiveness of addiction treatment.³¹ Bupropion is effective in the treatment of MDD³² and is generally ineffective in the management of OCD.³³ However, in our patient, the profile of depressive symptoms, with overwhelming anhedonia, suggested the bupropion may be effective. He experienced significant improvement, which persisted after the methadone was discontinued.

The treatment of choice for OCD is use of Serotonin Reuptake Inhibitors (SRIs).^{34,35} For OCD, the number needed to treat at standard doses of SRIs is approximately 5, and non-responders do not obtain significant improvement with dose escalation.³⁵ Nonetheless, successful treatment of OCD will improve outcomes overall for a patient with comorbidity with SUD.¹¹ The success of our patients in discontinuing the concomitant opiate after treatment was initiated for the OCD or depression is consistent with the finding that when these patients are engaged in successful psychiatric treatment, they have lower rates of active substance use than the general population.^{11,36}

Ultimate success in addressing addiction in the presence of OCD and depression necessitates collaboration between psychiatric and addiction medicine professionals. The Addiction Treatment Center protocol addresses the primary substance problem and coexisting psychiatric conditions with both medications and individual and group therapy focusing on support, the 12 steps, and Cognitive-Behavioral Therapy (CBT).³⁷

Conclusions

The complex interplay between OCD, MDD, and addiction underscores the need for specialized, multidisciplinary care. Tailored treatment plans that consider the nuances of these conditions can lead to more favorable outcomes, as exemplified by the successful cases pre-

sented here. By addressing the intricate relationship between these mental health disorders and addiction, clinicians can better navigate the challenges and offer hope for comprehensive recovery in affected individuals.

List of acronyms

OCD, Obsessive-Compulsive Disorder
MDD, Major Depressive Disorder
SUD, Substance Use Disorder
DSM, Diagnostic and Statistical Manual
SRI, Serotonin-Reuptake Inhibiting
CBT, Cognitive-Behavioral Therapy

Funding

None.

Conflict of interest

None.

Ethics approval and consent to participate

No ethical committee approval was required for this case report by the Department, because this article does not contain any studies with human participants or animals. Informed consent was obtained from the patients included in this study.

Patient consent for publication

The patients gave their written consent to use their personal data for the publication of this case report and any accompanying images.

Availability of data and materials

All data underlying the findings are fully available.

Corresponding author

Masoud Doroodgar, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
ORCID ID: 0000-0002-0431-2488
E-mail: masouddoroodgar@yahoo.com

Riffat S. El-Mallakh
ORCID ID: 0000-0002-4992-8016
E-mail: Riffat.elmallakh@louisville.edu

Jamal Shams
ORCID ID: 0000-0002-1461-5140
E-mail: j_shams@sbsmu.ac.ir

Moein Doroodgar
ORCID ID: 0000-0001-8434-692X
E-mail: mdoroodgar@gmail.com

References

1. Kessler RC, Berglund P, Demler O, et al. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. *Arch Gen Psychiatry* 2005;62:593–602.
2. Leshner AI. Addiction is a brain disease, and it matters. *Science* 1997;278:45-7.
3. McLellan AT. Substance misuse and substance use disorders: Why do they matter in healthcare? *Trans Am Clin Climatol Assoc* 2017;128:112-30.
4. U.S. Department of Justice, National Drug Intelligence Center. National Drug Threat Assessment 2011. Published August 2011. Accessed 31 October 2023. Available from: <https://www.justice.gov/archive/ndic/pubs/44/44849/44849p.pdf>
5. Mattson CL, Tanz LJ, Quinn K, et al. Trends and geographic patterns in drug and synthetic opioid overdose deaths – United States, 2013 – 2019. *MMWR Morb Mortal Wkly Rep* 2021;70:202-7.
6. Ross S, Peselow E. Co-occurring psychotic and addictive disorders: Neurobiology and diagnosis. *Clin Neuropharmacol* 2012;35:235-43.
7. Veale D, Roberts A. Obsessive-compulsive disorder. *BMJ* 2014;348:g2183.
8. American Psychiatric Association. Diagnostic and statistical manual of mental disorders (5th ed.). American Psychiatric Press, Washington, DC. 2013.
9. Conway KP, Compton W, Stinson FS, Grant BF. Lifetime comorbidity of DSM-IV mood and anxiety disorders and specific drug use disorders: Results from the National Epidemiologic Survey on Alcohol and Related Conditions. *J Clin Psychiatry* 2006;67:247-57.
10. Virtanen S, Kuja-Halkola R, Sidorchuk A, et al. Association of obsessive-compulsive disorder and obsessive-compulsive symptoms with substance misuse in 2 longitudinal cohorts in Sweden. *JAMA Netw Open* 2022;5:e2214779.
11. Mancebo MC, Grant JE, Pinto A, Eisen JL, Rasmussen SA. Substance use disorders in an obsessive compulsive disorder clinical sample. *J Anxiety Disord* 2009;23:429-35.
12. Quarantini LC, Torres AR, Sampaio AS, et al. Comorbid major depression in obsessive-compulsive disorder patients. *Compr Psychiatry* 2011;52:386-93.
13. Hunt GE, Malhi GS, Lai HMX, Cleary M. Prevalence of comorbid substance use in major depressive disorder in community and clinical settings, 1990-2019: Systematic review and meta-analysis. *J Affect Disord* 2020;266:288-304.
14. Brenner P, Brandt L, Li G, et al. Treatment-resistant depression as risk factor for substance use disorders-a nation-wide register-based cohort study. *Addiction* 2019;114:1274-82.
15. Badiani A, Belin D, Epstein D, et al. Opiate versus psychostimulant addiction: the differences do matter. *Nat Rev Neurosci* 2011;12:685-700.
16. Grassi G. Addicted to compulsion: Assessing three core dimensions of addiction across obsessive-compulsive disorder and gambling disorder. *CNS Spectrums*. 2020. doi:10.1017/S1092852919000993

Obsessive-compulsive disorder, major depressive disorder, and addiction: the vicious relationship

Eur J Transl Myol 34 (4) 13108, 2024 doi: 10.4081/ejtm.2024.13108

17. Kelly TM, Daley DC, Douaihy AB. Treatment of substance abusing patients with comorbid psychiatric disorders. *Addict Behav* 2012;37:11-24.
18. Torrens M, Rossi PC, Martinez-Riera R, et al. Psychiatric co-morbidity and substance use disorders: treatment in parallel systems or in one integrated system? *Subst Use Misuse* 2012;47:1005-14.
19. Kelly TM, Daley DC. Integrated treatment of substance use and psychiatric disorders. *Soc Work Public Health* 2013;28:388-406.
20. Agabio R, Trogu E, Pani PP. Antidepressants for the treatment of people with co-occurring depression and alcohol dependence. *Cochrane Database Syst Rev* 2018;4:CD008581.
21. Hassan AN, Howe AS, Samokhvalov AV, et al. Management of mood and anxiety disorders in patients receiving opioid agonist therapy: Review and meta-analysis. *Am J Addict* 2017;26:551-63.
22. Xu J, Hao Q, Qian R, et al. Optimal dose of serotonin reuptake inhibitors for obsessive-compulsive disorder in adults: A systematic review and dose-response meta-analysis. *Front Psychiatry* 2021;12:717999.
23. SAMHSA, Substance Abuse and Mental Health Services Administration. Obsessive-compulsive disorder and substance use disorders. *Advisory* 2016;15:1-9.
24. Torres AR, Ramos-Cerqueira AT, Ferrão YA, et al. Suicidality in obsessive-compulsive disorder: Prevalence and relation to symptom dimensions and comorbid conditions. *J Clin Psychiatry* 2011;72:17-26; Quiz 119-20.
25. Satel SL, McDougale CJ. Obsessions and compulsions associated with cocaine abuse. *Am J Psychiatry* 1991;148:947.
26. Koran LM, Aboujaoude E, Bullock KD, et al. Double-blind treatment with oral morphine in treatment-resistant obsessive-compulsive disorder. *J Clin Psychiatry* 2005;66:353-9.
27. Sun J, Li Z, Buys N, Storch EA. Correlates of comorbid depression, anxiety and helplessness with obsessive-compulsive disorder in Chinese adolescents. *J Affect Disord* 2015;174:31-7.
28. Tibi L, van Oppen P, van Balkom AJLM, et al. The long-term association of OCD and depression and its moderators: A four-year follow up study in a large clinical sample. *Eur Psychiatry* 2017;44:76-82.
29. Remijnse PL, van den Heuvel OA, Nielen MM, et al. Cognitive inflexibility in obsessive-compulsive disorder and major depression is associated with distinct neural correlates. *PLoS One* 2013;8:e59600.
30. Rickelt J, Viechtbauer W, Lieverse R, et al. The relation between depressive and obsessive-compulsive symptoms in obsessive-compulsive disorder: Results from a large, naturalistic follow-up study. *J Affect Disord* 2016;203:241-7.
31. Moritz S, Rufer M, Fricke S, et al. Quality of life in obsessive-compulsive disorder before and after treatment. *Compr Psychiatry* 2005;46:453-9.
32. Dhillon S, Yang LP, Curran MP. Spotlight on bupropion in major depressive disorder. *CNS Drugs* 2008;22:613-7.
33. Vulink NCC, Denys D, Westenberg HGM. Bupropion for patients with obsessive-compulsive disorder: An open-label, fixed-dose study. *J Clin Psychiatry* 2005;66:228-30.
34. Kellner M. Drug treatment of obsessive-compulsive disorder. *Dialogues Clin Neurosci* 2010;12:187-97.
35. Pittenger C, Bloch MH. Pharmacological treatment of obsessive-compulsive disorder. *Psychiatr Clin North Am* 2014;37:375-91.
36. Bakhshaie J, Storch EA, Zvolensky MJ. Obsessive-compulsive symptoms and problematic alcohol use: The explanatory role of drinking motives. *Addict Behav* 2021;115:106734.
37. Öst LG, Enebrink P, Finnes A, et al. Cognitive behavior therapy for obsessive-compulsive disorder in routine clinical care: A systematic review and meta-analysis. *Behav Res Ther* 2022;159:104170.

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Submitted: 15 September 2024.

Accepted: 4 October 2024.

Early access: 13 November 2024.